NRXPNRX Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of NRX Pharmaceuticals, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRXP본 종목 | $145M#9 | — | — | 118.6x#4 | — | -13.9%#7 | -1324.4%#4 | — | — | — | — | — |
| ORMP | $192M#2 | 1.1x#1 | 1.0x#3 | 96.1x#3 | — | 573.1%#2 | -754.4%#3 | 0.0%#2 | -4.4%#3 | — | 97.9%#2 | — |
| ORGO | $180M#3 | — | 1.2x#5 | 0.3x#1 | 17.0%#1 | 4011.1%#1 | 7.9%#1 | 25.0%#1 | 23.2%#1 | — | -71.3%#6 | — |
| NERV | $167M#4 | — | — | — | — | -20492.7%#13 | — | — | — | — | — | — |
| RNA | $163M#5 | — | 0.8x#2 | — | — | — | — | 0.0%#3 | — | — | -77.1%#7 | — |
| CNTN | $162M#6 | — | 0.4x#1 | — | — | -194.5%#10 | — | -7.9%#4 | — | — | — | — |
| LFCR | $158M#7 | — | — | 1.2x#2 | 0.5%#2 | -422.5%#11 | -13.4%#2 | — | -28.7%#4 | 3#1 | -47.4%#5 | — |
| SPRB | $156M#8 | — | 1.9x#7 | — | -100.0%#4 | 26.5%#5 | — | -46.5%#5 | — | — | 536.0%#1 | — |
| CRBP | $140M#10 | — | 1.4x#6 | — | -100.0%#4 | -95.3%#9 | — | -76.8%#8 | -93.1%#5 | — | -29.9%#4 | — |
| IMUX | $138M#11 | 5.0x#2 | 1.1x#4 | — | — | 3.3%#6 | — | -76.2%#7 | — | — | 23.9%#3 | — |
| CURX | $135M#12 | — | 28.2x#11 | — | — | -1068.8%#12 | — | -88.2%#9 | — | — | — | — |
| UNCY | $133M#13 | — | 2.5x#8 | 196.8x#5 | -29.0%#3 | 27.7%#4 | -4372.9%#5 | -49.8%#6 | — | — | — | — |
| APMD | $1.1B#1 | — | — | — | — | — | — | — | — | — | — | — |
| HURA | $129M#14 | — | 7.0x#9 | — | — | -34.8%#8 | — | -167.6%#10 | -0.1%#2 | — | — | — |
| BMEA | $126M#15 | — | 10.4x#10 | — | — | 55.4%#3 | — | -509.2%#11 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice